Orthomyxoviridae Infections  >>  Flublok (influenza vaccine)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Flublok (influenza vaccine) / Sanofi, Ildong, Shionogi
NCT00980447: Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Completed
2
90
Japan
UMN-0501, UMN-05
UMN Pharma Inc.
Influenza, Virus Diseases
12/09
12/09
NCT00336453: Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

Completed
1/2
156
US
Influenza Vaccination, FluBlok, Fluzone, rHA, rHA0, recombinant hemagglutinin, TIV
Protein Sciences Corporation
Influenza
07/07
07/07

Download Options